Mohamed El-Khalawany

Mohamed El-Khalawany

Auto-generated profile, based on publicly available information

Mohamed El-Khalawany

Department of Dermatology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2012 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
MEMohamed A. El-Khalawany
Mohamed A. El-Khalawany
HHHatem Hassan
Hatem Hassan
DSDalia Shaaban
Dalia Shaaban
NGNoha Ghonaim
Noha Ghonaim
BEBayoumi Eassa
Bayoumi Eassa

25 June 2012 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MEM. El‐Khalawany
M. El‐Khalawany
NAN. Al‐Mutairi
N. Al‐Mutairi
MSM. Sultan
M. Sultan
DSD. Shaaban
D. Shaaban

1 February 2015 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
MEMohamed El-Khalawany
Mohamed El-Khalawany
SFSameh Fawzy
Sameh Fawzy
ASAsmaa Saied
Asmaa Saied
MSMohammed Al Said
Mohammed Al Said
AAAhmed Amer
Ahmed Amer
BEBayoumi Eassa
Bayoumi Eassa

30 January 2011 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
BEBayoumy I. Eassa
Bayoumy I. Eassa
AAAmany A. Abou-Bakr
Amany A. Abou-Bakr
MEMohamed A. El-Khalawany
Mohamed A. El-Khalawany
Immunotherapy for treatment of recalcitrant warts was used through different modalities including intralesional injection of purified protein derivative (PPD), which is an extract of Mycobacterium tuberculosis, used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. This method is used to evaluate the efficacy of a new approach of intradermal injection of PPD in the treatment of anogenital warts in pregnant women. A total of 40 pregnant women, aged 20-35 years, and presented with anogenital warts were enrolled in this study. Human papillomavirus (HPV) typing was done using the GP5+/GP6+ PCR assay. The patients were treated with weekly injections of PPD given intradermally in the forearms, and evaluated for the response regularly. HPV type-6 was the predominant genotype (67.5%). Overall, the improvement in this study was 85% and was related to the extent of tuberculin reactivity. Nineteen (47.5%) patients demonstrated complete clearance, 15 (37.5%) had partial response, and three (7.5%) had minimal response. Three (7.5%) cases did not respond to treatment. Side effects were minimal and insignificant. Treatment of anogenital warts in pregnant women with intradermal injection of PPD was found to be a unique, safe, and effective modality of immunotherapy.

12 November 2013 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
AEAbd El-Shakor El-Mohamady
Abd El-Shakor El-Mohamady
IMIbrahim Mearag
Ibrahim Mearag
MEMohamed El-Khalawany
Mohamed El-Khalawany
AEAhmed Elshahed
Ahmed Elshahed
HSHisham Shokeir
Hisham Shokeir
AMAnas Mahmoud
Anas Mahmoud

6 August 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MRMahmoud A. Rageh
Mahmoud A. Rageh
MEMohamed El‐Khalawany
Mohamed El‐Khalawany
SIShady Mahmoud Attia Ibrahim
Shady Mahmoud Attia Ibrahim